Bullish & Foolish
Full ADGM fundamentals All 466 on the Survival Watch

ADGMADAGIO MEDICAL HOLDINGS, INC.

Is Adagio Medical Holdings struggling financially?

Yes, by its own account. Adagio Medical Holdings told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$14.4M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$7.7M

÷

Cash burned over the last 12 months

$19.4M

What Adagio Medical Holdings told the SEC

…collaborations, strategic alliances and marketing or distribution arrangements. Management intends to mitigate the conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern entity by (i) negotiating other cash equity or debt financing in the short-term, (ii) continuing to pursue the necessary regulatory approvals to launch commercially in the U.S. market,…

ADAGIO MEDICAL HOLDINGS, INC., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 44.4% share-count increase The company issued stock. Each share now owns 30.8% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.

Other Biotech/Pharma companies that filed the doubt